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Introduction
Photodynamic therapy (PDT) is a new treatment 
modality in which a combination of a photosensi-
tizer and visible light is programmed to result in 
the destruction of selected cells. In 1987, Malik and 
Lugaci1 first reported the used of endogenous pro-
toporphyrins as clinical photosensitizing agents. 
Later in 1990, Divaris et al.2 proposed a new approach 
to PDT, which involves the photosensitizer prodrug, 
5-aminolevulinic acid (ALA). ALA is a metabolic 
prodrug of protoporphyrin IX (PpIX), a photosen-
sitizing agent, in the heme biosynthesis pathway. 
Endogenous synthesis of ALA is regulated by the 
synthesis of heme via feedback control; following 
the exogenous administration of ALA, the feedback 
mechanism is bypassed with subsequent overpro-
duction and accumulation of porphyrin precursors, 
the predominant one of which is PpIX.3 The use of 
PpIX generated through the heme biosynthetic path-
way after administration of ALA has many applica-
tions in PDT against various cancers.4,5 A simplified 
Background/purpose: Using a topical formulation of 5-aminolevulinic acid (ALA), 
a mediated photodynamic therapy (PDT) was developed to treat oral precancerous 
and cancerous lesions. Several clinical results demonstrated that this special ALA 
preparation containing Carbopol 971P (CP971P), a bioadhesive polymer, resulted in 
a satisfactory PDT effect. It is believed that this PDT efficacy may be due to the 
increased bioadhesion of the preparation at the treatment site. We investigated 
whether there was a beneficial effect of CP971P on ALA PDT in vitro.
Materials and methods: CP971P was co-incubated with ALA in a cell culture sys-
tem. The effect of CP971P was evaluated by monitoring the uptake of ALA, the 
fluorescence intensity of protoporphyrin IX, and the cell survival rate.
Results: The polymer was found to enhance the fluorescence intensity of protopor-
phyrin IX and the subsequent PDT effect when concurrently dosed with ALA.
Conclusion: Our results showed that a formulation of ALA containing C971P could 
provide a better ALA PDT effect in cancer treatment.
Received: Nov 14, 2009
Accepted: Feb 20, 2010
KEY WORDS:
aminolevulinic acid;
Carbopol;
photodynamic therapy;
protoporphyrin IX
Enhancement of 5-aminolevulinic acid-induced 
photodynamic therapy by a bioadhesive polymer
Shu-Fang Chang,1 Yu-Tsai Yang,2 Wei-Ling Li,3 Che-Tong Lin,2 
Tsuimin Tsai2,3*
1Department of Dentistry, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
2College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
3Graduate Institute of Biomedical Materials and Engineering, Taipei Medical University, Taipei, Taiwan
Excipient effect on photodynamic therapy 31
schematic expression of ALA PDT is shown in Fig. 1. 
The formation of one PpIX molecule requires eight 
ALA molecules for synthesis. Selective PpIX accu-
mulation may be related to several factors, such 
as increased uptake of ALA, a low concentration of 
iron, a low activity of ferrochelatase, and a high ac-
tivity of porphobilinogen deaminase in tumor cells.6 
The passage of ALA through the cell membrane is 
restricted by the rate of uptake by neoplastic cells 
and its poor diffusion through tissues and cellular 
membranes.3 In order to increase its transport across 
cellular membranes, rather high concentrations of 
ALA generally must to be applied over long periods 
of time. Except for the Levulan Kerastick Topical 
Solution7 and a sol-gel preparation,8−10 the reasons 
for including any single vehicle material in the for-
mulation of most ALA formulations published in the 
literature were not explained. The Levulan Kerastick 
Topical Solution and the sol-gel preparation showed 
comparatively better ALA PDT results in clinical 
treatments, and the reason may have been due to 
a rational formulation design that ensured the per-
formance of ALA and the formation the photosen-
sitizer, PpIX, and a subsequent PDT effect upon 
irradiation. The Levulan Kerastick Topical Solution 
is a two-component system: one component con-
taining 1.5 mL of solution vehicle, and the other 
component containing 354 mg of ALA HCl as a dry 
solid. The reason for the two-component system is 
mainly due to stability concerns with ALA. ALA is 
not stable in solution and easily undergoes dimeri-
zation, so it is better to keep it in a dry powder form 
during storage. Since the Levulan Kerastick Topical 
Solution is mainly for skin application, the solution 
vehicle they include in the preparation is basically 
for enhancing penetration of ALA through the skin. 
The target of the sol-gel preparation is the oral mu-
cosa, and a combination of a mucoadhesive polymer 
and thermal-responsive polymer is included to en-
hance the retention time of ALA at the application 
site in order to increase drug uptake at the target 
site.8−10 Recently, the ALA sol-gel formulation was 
reported to exert a satisfactory result for skin wart 
treatment.11 In that report, the authors reportedly 
achieved a complete response 3 weeks after ALA 
PDT, and no recurrence was observed for up to 2 
years in 94% of patients. However, the reason d this 
clinical result using the ALA sol-gel was better than 
those using ALA cream12 is not clear.
Recently, a new field of “polymer therapeutics” 
has garnered lots of attention for pharmaceutical 
formulators, and mucoadhesive polymers seem to 
have the potential to enhance the performance 
of active ingredients.13 It would be interesting to 
study whether the mucoadhesive polymer, Carbopol 
971P (CP971P), in the ALA sol-gel preparation8−11 
holds the answer as to why the sol-gel formulation 
showed a better PDT effect than the traditionally 
favored cream preparation.12 Carbopol polymers 
(including CP971P) are generally regarded as safe 
polymers composed of acrylic acid crosslinked with 
polyalkenyl ethers or divinyl glycol.14 Carbopol poly-
mers are commonly used in oral suspensions, tab-
lets, and topical formulations, and their mucoadhesive 
properties provide intimate contact between the 
dosing formulation and the mucosal surface, re-
sulting in prolonged residence time at the site of 
absorption. Since the clinical results demonstrated 
that the ALA sol-gel preparation can produce a sat-
isfactory PDT effect on oral cancers and precan-
cerous lesions,8−10 it would be interesting to know 
whether such a formulation can benefit other mu-
cous routes, such as the lung. In this study, the effect 
of CP971P on a PpIX formation and the subsequent 
PDT effect after incubation with ALA in cell culture 
systems were studied.
Materials and methods
Cell culture conditions and ALA incubation
Two cell lines were tested for the effect of CP971P 
on ALA PDT. KB cells (ATCC CCL-17; American Type 
Culture Collection, Manassas, VA, USA), originally 
obtained from an epidermal carcinoma of the mouth, 
were cultured in Eagle’s minimum essential medium 
(Sigma, St. Louis, MO, USA) with 10% fetal bovine 
serum (FBS) (Gibco, Gaithersburg, MD, USA). CL1-0 
cells, established from a 64-year-old man with a 
poorly differentiated lung adenocarcinoma, were 
kindly provided by the National Health Research 
Institutes (Miaoli, Taiwan). A stock culture of CL1-0 
cells was maintained in RPMI 1640 (Sigma) with 
10% FBS. Cell cultures were maintained at 37ºC in a 
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Fig. 1 Schematic expression of the mechanism of 5-ami-
nolevulinic acid (ALA) photodynamic therapy (PDT). Eight 
ALA molecules form one protoporphyrin IX (PpIX) molecule 
via the heme biosynthesis pathway. Upon suitable light 
exposure, the ground state of PpIX can jump to a higher 
energy state (excited state). When an oxygen molecule 
is available, formation of singlet oxygen through energy 
transfer from the excited PpIX can be used to induce 
cellular damage.
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humidified atmosphere of 95% air and 5% CO2. The 
cells seeded in culture plates or dishes were incu-
bated with 1mM ALA (with or without CP971P, di-
luted in serum-free medium and neutralized to pH 
7.2 with NaOH immediately before use) for 3 hours. 
CP971P was kindly provided by Lubrizol (Wickliffe, 
OH, USA), and a stock solution (1% wt/vol) was pre-
pared by slowly adding the polymer powder into 
water with stirring for 3 hours or longer. Various con-
centrations of CP971P were obtained by taking al-
iquots of the stock solution and diluting them with 
water.
Measurement of ALA-induced PpIX 
fluorescence by flow cytometry
Cells were seeded in triplicate in six-well plates con-
taining 2 ˜  105 cells per well and incubated for 24 
hours at 37ºC. Afterwards, cells were incubated in 
phenol red-free, serum-free medium containing 1mM 
ALA for 3 hours. Following ALA incubation, cells were 
trypsinized, removed from the culture dishes, and 
resuspended in fresh culture medium supplemented 
with serum. Cellular fluorescence was quantified with 
a Coulter EPICS XL-MCL flow cytometer (Beckman 
Coulter, Miami, FL, USA), and 10,000 cells were an-
alyzed. The ALA-induced photosensitizer, PpIX, was 
excited by an argon ion laser emission at 488 nm and 
collected by a photomultiplier tube after passing 
through a 670-nm long-pass filter.
Photodynamic treatment
For photodynamic treatment, cells were seeded in 
96-well plates (at about 6000 cells/well) and grown 
overnight in complete medium. After incubation 
with 1mM ALA with or without 0.05% CP971P for 
3 hours, cells were exposed to light at doses of 0−
32 J/cm2. The light source was a light-emitting diode 
at 60 mW, with a wavelength emission of red light 
at 630 ± 5 nm. After irradiation, cells were incubated 
with fresh complete medium for another 24 hours 
until further analysis.
Cell viability assay
The PDT-induced phototoxicity of test cells was 
determined by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay. Each 
individual phototoxic experiment was performed 
in triplicate. The MTT assay is based on the activ-
ity of mitochondrion dehydrogenase, which can re-
duce a water-soluble tetrazolium salt to a purple 
insoluble formazan product.15 The resulting formazan 
crystals were dissolved by the addition of dimethyl 
sulfoxide, and analyzed spectrophotometrically at 
an absorbance of 570 nm. Cells exposed to ALA but 
without light were used as the control. The cell 
survival rate (%) was calculated as: (mean optical 
density value of treated cells/mean optical den-
sity value of control cells) ˜  100%.
Determination of ALA uptake
[14C]ALA hydrochloride was purchased from New 
England Nuclear (Boston, MA, USA) and used in this 
part of the study. Unlabelled ALA was dissolved 
in phosphate-buffered saline (PBS), and [14C]ALA 
was added so that the final solution contained 
0.0222 MBq/mL. Cells were washed twice with 0.5 mL 
PBS at 37ºC and incubated with 0.3 mL radiolabeled 
ALA solution in the culture medium without FBS. At 
certain time intervals, the reaction was stopped, 
and cells were washed four times with 0.5 mL ice-
cold PBS. Cells were then disrupted in 0.2mM NaOH 
and transferred to vials containing 5 mL cocktail 
scintillation fluid (Beckman Ready Protein; Beckman 
Instruments, Fullerton, CA, USA). The radioactive 
content of the samples was determined by a Beckman 
LS 1801 counter (Beckman Instruments, Karlsruhe, 
Germany)16. Data are expressed as the apparent 
ALA concentration in pmol/mg of protein, calcu-
lated from the amount of radioactivity in cells.
Statistical analysis
Data are presented as the mean ± standard error of 
the mean. At least three independent experiments 
were performed for each experiment. An unpaired 
t test was used to establish the significance of dif-
ferences between groups. Differences were con-
sidered statistically significant at P < 0.05.
Results and Discussion
The effect of CP971P on the relative fluorescence 
of ALA-converted PpIX in CL1-0 cells is shown in 
Fig. 2. The fluorescence intensity was measured 
by flow cytometry after incubation with 1mM ALA 
in the presence or absence of CP971P for 3 hours. 
As shown in Fig. 2, in the presence of CP971P, the 
fluorescence intensity increased in a concentration-
dependent manner until it reached a plateau at 
0.05%. A further increase in the CP971P concentra-
tion to 0.1% did not further increase the fluorescence 
intensity. In fact, the PpIX fluorescence intensity 
of cells treated with 0.05% CP971P was almost 
double that without CP971P. A similar effect of 
CP971P on the formation of PpIX was found with 
oral epithelial carcinoma cells, and the results are 
given in Table 1. For KB cells, even 0.001% CP971P 
showed 23% enhancement of the PpIX fluorescence. 
The higher fluorescence intensity indicated that 
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more ALA-converted PpIX was present in the pres-
ence of CP971P, suggesting that more reactive oxygen 
species were produced to kill cancer cells after light 
irradiation. However, it should be noted that KB cells 
were shown to be contaminated by HeLa cells.17 In 
this regard, it is necessary to perform more studies 
in other representative cell lines derived from oral 
squamous cell carcinoma.
To examine the efficacy of PDT, an MTT assay 
was performed to evaluate the cell-killing effect. 
As shown above, 1 mM ALA combined with 0.05% 
CP971P showed the strongest PpIX fluorescence. 
Therefore, the possible increased efficacy of PDT 
by CP971P was evaluated using this condition, and 
the results are shown in Fig. 3. In the absence of 
CP971P, the cell survival rate decreased in a light-
dose relationship as expected. In the presence of 
0.05% CP971P, the cell survival rate still showed a 
decreasing tendency with an increasing light dose. 
However, inclusion of 0.05% CP971P in the ALA PDT 
study resulted in a more significant enhancement 
of cell death, especially at the light dose ranges of 
8 and 16 J/cm2. Cell survival rates without CP971P 
were around 80% and 60% under light doses of 8 and 
16 J/cm2, respectively. However, in the presence 
of CP971P, the cell survival rate was down to 50% 
and 20% under light doses of 8 and 16 J/cm2, re-
spectively. The result is not surprising, because the 
presence of CP971P was found to increase the for-
mation of PpIX. An increase in the photosensitizer 
is expected to increase the phototoxicity of cells 
where the photosensitizer resides. The results of 
the increased PpIX fluorescence and enhanced kill-
ing effect by adding a trace amount of a common 
polymer (such as Carbopol) are encouraging and of 
high potential in drug development. If PDT’s effi-
cacy can be improved simply by adding a much 
cheaper polymer concurrently with the photosen-
sitizer, the formulator can utilize such information 
and design a less expensive drug for PDT.
The conversion of ALA to PpIX was correlated 
with several steps, including the amount of ALA 
transported into cells and the activity of several 
enzymes involved in the heme synthesis pathway 
(Fig. 4). CP971P is a macromolecular polymer with 
an average molecular weight of 106 kDa, and its 
penetration through cell membranes is almost im-
possible. There fore, the enhancement of PpIX flu-
orescence, as well as ALA-PDT’s effect, could have 
been due to an increase in the passive diffusion of 
ALA into cells or the active uptake of ALA by cells 
in the presence of CP971P. By tracing the intensity 
of labeled ALA in cells after 3 hours of incubation 
and removal of the culture medium, it was found 
that the uptake of ALA by CL1-0 cells was greatly 
enhanced in the presence of CP971P in the system 
as shown in Fig. 5. In the presence of CP971P, ALA 
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Fig. 2 Effect of Carbopol 971P (CP971P) on 5-aminole-
vulinic acid (ALA)-induced relative fluorescence of pro-
toporphyrin IX (PpIX) in CL1-0 cells measured by flow 
cytometry. Cells were measured after incubation with 1mM 
ALA with various concentrations of CP971P for 3 hours. 
The PpIX fluorescence was acquired by flow cytometry. 
*P < 0.01.
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Fig. 3 Presence of 0.05% Carbopol 971P (CP971P) and 
light dose dependency of 5-aminolevulinic acid (ALA) 
photodynamic therapy on the survival rate of CL1-0 cells 
using the MTT assay. Cells were incubated with 1mM ALA 
for 3 hours and subjected to various doses of light illumi-
nation. *P < 0.01.
Table 1. Effect of Carbopol 971P (CP971P) on the flu-
orescence intensity of protoporphyrin IX (PpIX) in KB 
cells incubated with 1mM 5-aminolevulinic acid (ALA) 
for 3 hours
Cells incubated Increased PpIX 
Pwith 1mM ALA fluorescence
for 3 hours intensity (%)
No CP971P  0 
0.001% CP971P 23 < 0.05
0.01% CP971P 33 < 0.05
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uptake increased in a concentration-dependent 
manner. This result is consistent with the increased 
PpIX fluorescence intensity, where the PpIX fluores-
cence also showed an increasing tendency in the 
presence of CP971P (Fig. 2). However, there was 
almost no difference in the PpIX fluorescence with 
0.05% or 0.1% CP971P, but the uptake was higher 
with 0.1% CP971P. The presence of macromolecules 
in the culture medium may have been responsible 
for this. Since PpIX can only be formed in cells, 
there is no need to replace the culture medium 
after ALA incubation. In this study, after culturing 
with ALA (whether or not in the presence of CP971P), 
cells along with the culture medium were sub-
jected to flow cytometric measurement without pre-
washing or replacing the medium. There fore, the 
added CP971P was in the culture medium through-
out the study. The effect of pharmaceutical excipi-
ents interfering with the measured absorbances of 
a drug was reported by Fuerte and Maldonado,18 
and predictions of the drug concentration in the 
analyzed samples can be misleading because of 
the scattering effect of light. Since light scattering 
can affect both the absorbance and the emission of 
light, one possible reason could be due to a light-
scattering effect in the presence of macromolecules 
such as CP971P.
The cellular PpIX amount derived from ALA de-
pends on ALA uptake and the activity of enzymes 
involved in ALA PpIX’s conversion. ALA PDT-induced 
selective destruction of neoplastic lesions was attrib-
uted to an aberration of heme biosynthesis, such as 
the reduction of ferrochelatase activities or upregu-
lation of porphobilinogen deaminase, in tumor cells.16 
As shown in Fig. 5, CP971 significantly increased the 
uptake of ALA in a concentration-dependent man-
ner. Although 0.05% CP971 significantly increased the 
PpIX amount (Fig. 2), an increased concentration 
of CP971 did not further increase PpIX, which might 
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Fig. 5 Presence of Carbopol 971P (CP971P) on the uptake 
of 5-aminolevulinic acid (ALA) by CL1-0 cells with 3 
hours of incubation time. Cells were incubated with 1mM 
ALA (a mixture of cold and hot ALA, labeled with 14C) with 
various concentrations of CP971P for 3 hours. *P < 0.01.
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Fig. 4 Schematic expression of the formation of protoporphyrin IX (PpIX) through the heme formation pathway after 
external dosing of 5-aminolevulinic acid (ALA). The biosynthesis of heme occurs partly in the mitochondria and partly 
in the cytosol. PpIX is originally synthesized in the mitochondria.
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have been due to the maximum enzyme activity 
having already been achieved.
In conclusion, PDT is a new treatment modality 
for surface cancers such as skin cancers and oral 
cancers, and has shown potential in treating exter-
nally approachable sites. However, photosensitizers 
that can be used with PDT are extremely expensive. 
Although ALA, a photosensitizer precursor, is much 
less expensive than other photosensitizer drugs, it 
generally requires a larger dose and the cost is still 
rather high. To reduce the costs of PDT drugs, the 
field of excipient application is becoming more at-
tractive. In this study, we proved that a mucoadhe-
sive polymer, CP971P, can increase ALA uptake by 
cancer cells and the formation of PpIX.
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